[go: up one dir, main page]

FR2781160B1 - Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire - Google Patents

Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire

Info

Publication number
FR2781160B1
FR2781160B1 FR9808700A FR9808700A FR2781160B1 FR 2781160 B1 FR2781160 B1 FR 2781160B1 FR 9808700 A FR9808700 A FR 9808700A FR 9808700 A FR9808700 A FR 9808700A FR 2781160 B1 FR2781160 B1 FR 2781160B1
Authority
FR
France
Prior art keywords
adjust
subunit vaccine
amphipathic compound
amphipathic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9808700A
Other languages
English (en)
Other versions
FR2781160A1 (fr
Inventor
Anne Darbouret
Florence Brunel
Jorge Ronco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Pasteur Merieux Serum et Vaccines SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serum et Vaccines SA filed Critical Pasteur Merieux Serum et Vaccines SA
Priority to FR9808700A priority Critical patent/FR2781160B1/fr
Priority to EP99929389A priority patent/EP1093382A2/fr
Priority to PCT/FR1999/001604 priority patent/WO2000001345A2/fr
Priority to CA 2337048 priority patent/CA2337048A1/fr
Priority to AU46217/99A priority patent/AU4621799A/en
Priority to US09/720,863 priority patent/US6472159B1/en
Publication of FR2781160A1 publication Critical patent/FR2781160A1/fr
Application granted granted Critical
Publication of FR2781160B1 publication Critical patent/FR2781160B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR9808700A 1998-07-03 1998-07-03 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire Expired - Lifetime FR2781160B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR9808700A FR2781160B1 (fr) 1998-07-03 1998-07-03 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
EP99929389A EP1093382A2 (fr) 1998-07-03 1999-07-02 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
PCT/FR1999/001604 WO2000001345A2 (fr) 1998-07-03 1999-07-02 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
CA 2337048 CA2337048A1 (fr) 1998-07-03 1999-07-02 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
AU46217/99A AU4621799A (en) 1998-07-03 1999-07-02 Use of an amphipathic compound for providing an adjuvant to subunit vaccine
US09/720,863 US6472159B1 (en) 1998-07-03 1999-07-02 Use of an amphipathic compound for providing an adjuvant to a subunit vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9808700A FR2781160B1 (fr) 1998-07-03 1998-07-03 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire

Publications (2)

Publication Number Publication Date
FR2781160A1 FR2781160A1 (fr) 2000-01-21
FR2781160B1 true FR2781160B1 (fr) 2000-08-18

Family

ID=9528373

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9808700A Expired - Lifetime FR2781160B1 (fr) 1998-07-03 1998-07-03 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire

Country Status (6)

Country Link
US (1) US6472159B1 (fr)
EP (1) EP1093382A2 (fr)
AU (1) AU4621799A (fr)
CA (1) CA2337048A1 (fr)
FR (1) FR2781160B1 (fr)
WO (1) WO2000001345A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
CA2700808C (fr) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Utilisation de liposomes dans un vehicule composant une phase hydrophobe continue pour la delivrance de polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US20110070298A1 (en) * 2008-06-05 2011-03-24 Immunovaccine Technologies Inc. Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
CN103998058B (zh) 2011-10-06 2021-11-05 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
CN1073604A (zh) * 1991-12-01 1993-06-30 高真南 制备高免疫原性乙型肝炎疫苗的方法
ES2113119T3 (es) * 1993-08-06 1998-04-16 Opperbas Holding Bv Un metodo para la preparacion de vesiculas cargadas con estructuras biologicas, biopolimeros y/o oligomeros.
FR2726764B1 (fr) * 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
FR2730935A1 (fr) * 1994-12-21 1996-08-30 Vacsyn Sa Vaccin presentant une immunogenicite accrue
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US5753262A (en) 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof
WO1998048836A1 (fr) * 1997-04-30 1998-11-05 Merieux Oravax Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1

Also Published As

Publication number Publication date
CA2337048A1 (fr) 2000-01-13
US6472159B1 (en) 2002-10-29
EP1093382A2 (fr) 2001-04-25
WO2000001345A3 (fr) 2000-02-24
FR2781160A1 (fr) 2000-01-21
AU4621799A (en) 2000-01-24
WO2000001345A2 (fr) 2000-01-13

Similar Documents

Publication Publication Date Title
FR08C0004I2 (fr) Composition orale d' une dose pour une libération prolongée
HUP0202495A3 (en) Stable medicinal compositions for oral use
ID24568A (id) Kontrasepsi oral yang mengandung anti-estrogen plus progestin
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
EP1154316A4 (fr) Unite de presentation d'images a retroprojection
FR2781160B1 (fr) Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
FR2810323B1 (fr) Utilisation cosmetique d'un lipopeptide
FR2732217B1 (fr) Forme d'administration solide a usage oral
FR2759585B1 (fr) Formulations pharmaceutiques presentees sous forme seche pour l'administration orale d'un compose ammonium quaternaire cyclique
HUP0201667A3 (en) Oral form of administration
NO20021452L (no) Orale kontrollerte frigivelsesformuleringer
IT1313383B1 (it) Struttura efficiente di integratore a capacita' commutate integrato
FR2839453B1 (fr) Utilisation de novirhabdovirus modifies pour l'obtention de vaccins
FR2800280B1 (fr) Nouvelle composition vaccinale et utilisation d'agents tensioactifs comme adjuvants d'immunite
EE04220B1 (et) Kontrollitud vabanemisega levosimendani peroraalsed koostised
EE200200213A (et) Suukaudselt manustatav galantamiinilahus
NO981320D0 (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
IT1291622B1 (it) Uso dell'acido tioglicolico come agente depigmentante
EE9900516A (et) Sekretsioonivektori kasutamine viljastuskontrolliks peroraalse vaktsineerimise abil
IT1297758B1 (it) Dispositivo per l'ancoraggio di protesi dentarie
ITMI990276V0 (it) Astuccio contenente un set di strumenti per l'igiene orale
GB9911823D0 (en) New vaccine formulations
DK0980383T3 (da) Farmaceutisk acceptable salte af 3-hydroxy-østr-5(10)-en-17-on-3-sulfat aktive som østrogener
FR2793418B1 (fr) Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee
TW387466U (en) Plaster's trowel

Legal Events

Date Code Title Description
CA Change of address
CD Change of name or company name
CD Change of name or company name
PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20